Example: stock market
Comirnaty ( tozinameran
Comirnaty offers a high level of protection against COVID -19 which is a critical need in the current pandemic. The main trials showed that the vaccine has a high efficacy in all age groups. Most side effects are mild to moderate in severity and are gone within a few days.
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Steckbrief Impfstoff Comirnaty® von BioNTech/Pfizer
www.kbv.deSeite 3 von 4 / KBV / Steckbrief Impfstoff Comirnaty® von BioNTech/Pfizer / 25. Januar 2022 Wechselwirkungen Siehe aktuelle Fachinformation Wirksamkeit Die Wirksamkeit des Impfstoffes (erstes Auftreten von COVID-19 ab 7 Tagen nach Dosis 2) liegt bei 94,6 %.
EUROPEAN MEDICINES AGENCY
www.ema.europa.euCOMIRNATY Procedural steps taken and scientific information after the authorisation Application number II/0102 Scope Update of sections 4.8 and 5.1 of the SmPC in order to update safety and efficacy information 6 months post-dose 2 follow-up for adolescence 12 through 15 years of age based on updated interim results from
VACCINATION INFORMATION SHEET PFIZER-BIONTECH / …
www.moh.gov.sg4. How is the Pfizer-BioNTech / Comirnaty COVID-19 vaccine given? This vaccine is given as an injection into the muscle of your upper arm. 1 This includes transplant patients, cancer patients on active treatment, hematological cancers, persons on treatments that suppress the immune system, end-stage kidney disease and advanced or untreated HIV.